🔗 Share this article

As America proceeds with unprecedented revisions to its vaccination schedules, one figure has surfaced unexpectedly: Tracy Beth Høeg, a Danish American physician and public health researcher who initially gained attention by casting doubt on COVID-19 shots during the pandemic and has zeroed in on potential deaths following COVID-19 immunization in her short tenure at the FDA.

Proposed Overhauls to Pediatric Immunization Program

Agency leaders planned to announce major changes to the pediatric vaccination calendar recently, bringing the US with Denmark’s immunization schedule, according to reports – a substantial departure that would place the US out of step with many the international standard with no evidence for benefit. The planned update has been pushed back until the new year.

In place of the top vaccines chief, Dr. Høeg is set to present at the event. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the center this calendar year.

A New Direction at the Agency

Høeg's temporary position could signify a strengthened alliance between the drug and biologics centers as Dr. Høeg and Dr. Prasad solidify control at the regulatory agency – and it suggests a greater focus upon dismantling previously authorized immunizations at the FDA.

The new acting director has frequently advocated for ending some childhood immunization guidelines in the US in order to be more similar to Denmark, a society with comprehensive healthcare and a population roughly the size of the state of Wisconsin.

So far statements, she has kept her attention on immunizations – typically the responsibility of Dr. Prasad, chief of the FDA’s CBER – as opposed to pharmaceutical oversight.

Concerns Over Qualifications

Dr. Høeg has no apparent experience in drug development, regulation or leadership, which has been standard for former heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the commissioner and CBER since earlier this year.

“It seems she lacks to have the necessary background” for running the pharmaceutical oversight division, said Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She is not versed in leading a large organization. She lacks background in drug approvals.”

Former heads of CBER would “understand legal statutes and the research of drug development”, said Dr. Janet Woodcock. “Clearly, she has not acquired the type of experience that prior appointees who headed CBER have had.”

This division has an immense workload at the FDA, she emphasized.

“The public just zeroes in on the innovative therapies, but the generic program clears thousands of generic drugs. There’s a biologic copycat branch, non-prescription drug unit and other areas, and each of these must be managed,” she explained. “The responsibility you overlook, that is the part that I always told people is going to come back to haunt you.”

Additionally, a significant administrative element to the job, which supervises in excess of 5,000 personnel. “It’s a huge management job, if you execute it properly,” Woodcock added.

Response and Contentious Programs

When asked about questions about Høeg’s qualifications and whether this assignment indicates more teamwork among agency officials on vaccines, a representative stated that the “questions rely on inaccurate presumptions”.

“Her resume matches the functions of her job,” the official said, pointing to the period Høeg spent advising the FDA commissioner on “medication safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Dr. Høeg takes over the agency head's new fast-track approval initiative, a controversial rapid medication authorization process that allegedly concerned her preceding directors. “By what process are these drugs being chosen for this expedited pathway? Who is making the calls?” Howard said. “There’s a lot of confidentiality going on at the regulatory body right now.”

In general, he said, “the agency seems to be moving towards less stringent rules of most medications, with the exception of shots.”

Established Track Record on Immunizations

Regarding vaccines, Høeg has a more established, if problematic, past, some experts said. She released a research paper using unconfirmed crowd-sourced reports to determine the incidence of heart inflammation after Covid immunization. She consulted for the state of Florida surgeon general Dr. Joseph Ladapo, who allegedly have changed statistics to imply COVID-19 vaccines are more dangerous than they are.

Part of her “wish list” for the current administration featured altering regulations for new vaccines and discontinuing “non-essential” immunizations, she said post-election on a audio program. At the agency, Høeg has according to sources proposed excluding teenage boys from getting COVID-19 vaccinations.

“She’s an thorough ideologue who begins with her conclusions and reverse-engineers to retrofit the evidence in a very disingenuous, dishonest manner,” Dr. Howard stated.

Taking Control and a “Campaign of Retribution”

Dr. Høeg aligned with fellow dissenters, {like|